TY  - GEN 
AU  - Gale, Daniel
AU  - Agraz Pamplona, Irene
AU  - Zainab, Arslan
AU  - Esteban de la Rosa, Rafael José
AU  - Hall, Matthew
AU  - Krejci, Karel
AU  - Morales, Enrique
AU  - Safranek, Roman
AU  - Tesar, Vladimir
AU  - Torra, Roser
AU  - Lennon, Rachel
PY  - 2026
SN  - 1046-6673
SN  - 1533-3450
UR  - https://hdl.handle.net/10481/112615
AB  - The study (NCT06274489), evaluated setanaxib—a first-in-class NOX1/4 inhibitor—as a treatment to reduce fibrosis and inflammation in Alport syndrome (AS).
Key Findings from the Trial
1. Safety (Primary Endpoint)
The study met its primary safety...
LA  - eng
PB  - American Society of Nephrology
KW  - As
KW  - Alport Syndrome
KW  - Setanaxib
TI  - Safety and preliminary efficacy findings from a phase 2a randomized, double-blind, placebo-controlled trial of setanaxib in patients with Alport syndrome
DO  - 10.1681/ASN.20253w14s1fa
ER  -